Sipuleucel-T: immunotherapy for advanced prostate cancer.
Sipuleucel-T: immunotherapy for advanced prostate cancer.
复制标题
DOI：
10.2147/oaju.s13069
复制
发表时间：
2011-05-03
期刊：
影响因子：
--
通讯作者：
McNeel DG
中科院分区：
文献类型：
--
作者：
Olson BM;McNeel DG
前列腺癌仍然是老年男性最严重的疾病之一，在美国男性中，它是最常被诊断出的癌症，也是癌症相关死亡的第二大原因。对于患有无法治愈的转移性去势抵抗性疾病的患者，治疗方案长期以来一直侧重于各种化疗方法，这些方法虽能略微提高生存率，但可能伴有严重的副作用。然而，sipuleucel - T最近获得批准，为晚期疾病患者提供了一种额外的治疗选择，它已被证明有益且无化疗相关的副作用。Sipuleucel - T是一种基于抗原呈递细胞的主动免疫疗法，利用患者自身的免疫细胞，大概是为了激活针对肿瘤细胞的抗原特异性免疫反应。本综述重点关注sipuleucel - T作为前列腺癌治疗方法的研发和应用。具体而言，我们介绍了一些与晚期前列腺癌治疗相关的问题、导致sipuleucel - T获批的研发过程、sipuleucel - T的获批如何改变前列腺癌的临床治疗，以及当前和未来针对sipuleucel - T和其他晚期前列腺癌治疗方法正在进行的研究领域。
Prostate cancer continues to be one of the most serious afflictions of men of advanced age, remaining the most commonly diagnosed and second leading cause of cancer-related deaths in American men. The treatment options for patients with incurable metastatic, castrate-resistant disease have long focused on various chemotherapeutic approaches, which provide a slight survival benefit while being associated with potentially significant side effects. However, the recent approval of sipuleucel-T has given patients with advanced disease an additional treatment option that has demonstrated benefit without the side effects associated with chemotherapy. Sipuleucel-T is an antigen-presenting cell-based active immunotherapy that utilizes a patient’s own immune cells, presumably to activate an antigen-specific immune response against tumor cells. This review focuses on the development and implementation of sipuleucel-T as a therapy for prostate cancer. Specifically, we present some of the issues associated with the management of advanced prostate cancer, the research and development that led to the approval of sipuleucel-T, how the approval of sipuleucel-T could change the clinical management of prostate cancer, and current and future areas of investigation that are being pursued with regard to sipuleucel-T and other treatments for advanced prostate cancer.